SOURCE: Paragon Financial Limited

Paragon Financial Limited

January 31, 2012 08:20 ET

Biotech Industry Rallies -- Arena Pharmaceuticals and XOMA Poised for Growth

Paragon Report Provides Equity Research on Arena Pharmaceuticals & XOMA Corporation

NEW YORK, NY--(Marketwire - Jan 31, 2012) - Biotechnology stocks have been on a tear this month, gaining an impressive 11 percent. Reuters recently released an article arguing health-care costs are outpacing consumer inflation, leading government and industry to seek ways to cut costs. Reuters' 2012 biotech outlook says this could mean an even greater reliance upon drugs.The Paragon Report examines the outlook for companies in the Biotechnology industry and provides equity research on Arena Pharmaceuticals Inc. (NASDAQ: ARNA) and XOMA Corporation (NASDAQ: XOMA). Access to the full company reports can be found at:

www.paragonreport.com/ARNA
www.paragonreport.com/XOMA

Gunderson Capital Management argues that part of biotech's rally is being driven by expectations that President Barack Obama's health care reform plan may be repealed. Earlier this month House Republicans pushed through a resolution in support of a Constitutional amendment that would repeal Obamacare. House Resolution 1003 asks Congress to call a constitutional convention to propose an amendment to repeal the Affordable Care Act, which is also set to be challenged before the Supreme Court this year.

The Paragon Report provide investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters

XOMA is a leader in the discovery and development of novel antibody therapeutics. The Company's lead drug candidate is gevokizumab (XOMA 052), a humanized antibody that binds to the inflammatory cytokine interleukin-1 beta, or IL-1 beta. Earlier this month the company announced that it acquired U.S. rights to the perindopril franchise from Les LaboratoiresServier, XOMA's partner for its lead product candidate, gevokizumab.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer